Analysis revealed significantly higher R3HDM4 mRNA levels in tumor vs. normal tissues across multiple cancers, including ACC (adrenocortical carcinoma), BLCA (bladder urothelial carcinoma), BRCA (breast invasive carcinoma), KIRC, LIHC (liver hepatocellular carcinoma), LGG (lower grade glioma), and other common malignancies. This evidence concerns the gene R3HDM4 and central nervous system cancer.